BRCA2 and ovarian carcinoma: A retrospective cohort study from 2015 showed an increase of ovarian cancer risk following HRT both for pV-carriers in the BRCA1 gene (OR 1.66; 95% CI 0.89–3.08; p < 0.001) and in the BRCA2 gene (OR 3.04; 95% CI 1.19–7.8; p < 0.001) (Perri et al. 2015).